Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05193149
Other study ID # OSU-22220
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date November 13, 2023
Est. completion date June 30, 2029

Study information

Verified date November 2023
Source Ohio State University Comprehensive Cancer Center
Contact Dharini M Bhammar, PhD
Phone 6143669467
Email dharini.bhammar@osumc.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The investigators propose a randomized controlled trial to determine the effectiveness of inspiratory muscle training in improving exercise tolerance among stage 0-III obese breast cancer survivors.


Description:

Randomized controlled trial (RCT) where obese participants (N=133) are randomized to 2 arms: [i] IMT 4 wks + Exercise 12 wks, [ii] SHAM 4 wks + Exercise 12 wks).


Recruitment information / eligibility

Status Recruiting
Enrollment 78
Est. completion date June 30, 2029
Est. primary completion date June 30, 2028
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - completed active treatment for a Stage 0-III breast cancer diagnosis within 6 months to 5 years of enrollment. - obese as defined by a body mass index (BMI) of 30 to 50 kg/m2 - patients who are on adjuvant endocrine therapy will be allowed to participate. - sedentary (participating in less than 90 min of moderate intensity activity per week) and have at least one limitation in activity on the 10-question RAND-36 Physical Function Subscale to ensure some exercise intolerance Exclusion Criteria: - functional limitations that make independent exercise unsafe - current smokers - metastatic breast cancer - ongoing or active infection with recent antibiotics or steroids - heart disease precluding exercise (congestive heart failure, unstable angina pectoris, cardiac arrhythmia) - psychiatric illness/social situations that would limit compliance with study requirements - orthopedic or neuromuscular disorders or arthritis that preclude participation in exercise - unwilling or unable to follow protocol requirements - pregnant or nursing - any condition which in the investigator's opinion deems the subject an unsuitable candidate to participate in this study - presence of provokable ECG changes suggestive of heart disease, or dangerous arrhythmias or exercise induced hypertension, etc. during the cardiopulmonary exercise test - non-English speaking

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Inspiratory muscle training
Training of respiratory muscles
Exercise training
Supervised aerobic exercise intervention

Locations

Country Name City State
United States The Ohio State University Columbus Ohio

Sponsors (1)

Lead Sponsor Collaborator
Ohio State University Comprehensive Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in exercise tolerance Continuous variable assessed as time to exhaustion during a CWRET at 80% of peak work rate. Units: minutes. Baseline to 4 weeks
Primary Change in exercise tolerance Continuous variable assessed as time to exhaustion during a CWRET at 80% of peak work rate. Units: minutes. Baseline to 16 weeks
Secondary Change in inspiratory muscle strength Continuous variable, Maximal inspiratory pressure. Units: cm H20 Baseline to 4 weeks
Secondary Change in inspiratory muscle strength Continuous variable, Maximal inspiratory pressure. Units: cm H20 Baseline to 16 weeks
Secondary Change in inspiratory muscle endurance Continuous variable, Maximal voluntary ventilation in 12 seconds. Units: L/min Baseline to 4 weeks
Secondary Change in inspiratory muscle endurance Continuous variable, Maximal voluntary ventilation in 12 seconds. Units: L/min Baseline to 16 weeks
Secondary Change in exercise capacity Continuous variable, peak oxygen uptake. Units: L/min Baseline to 4 weeks
Secondary Change in exercise capacity Continuous variable, peak oxygen uptake. Units: L/min Baseline to 16 weeks
Secondary Change in dyspnea Continuous variable, mMRC dyspnea scale score. Units: score 0 to 4 Baseline to 4 weeks
Secondary Change in dyspnea Continuous variable, mMRC dyspnea scale score. Units: score 0 to 4 Baseline to 16 weeks
Secondary Change in fatigue Continuous variable, FACIT:F version 4 total score. Units: score 0 to 52 Baseline to 4 weeks
Secondary Change in fatigue Continuous variable, FACIT:F version 4 total score. Units: score 0 to 52 Baseline to 16 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Recruiting NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Recruiting NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A

External Links